Patrick Bonson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Patrick Bonson has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Philip D. Greenberg
Fred Hutchinson Cancer Center, Seattle, WA, USA
2 shared publications - Adam L. Burrack
Department of Microbiology and Immunology, University of Minnesota Medical School, Minneapolis, MN, USA
1 shared publication Andrew Binks
Department of Basic Science Education, Virginia Tech Carilion School of Medicine, Roanoke, USA
1 shared publication- Andrew W. Daman
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, USA
1 shared publication Ayaka Hulbert
1 shared publication- Breanna M. Bates
Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA 1
1 shared publication
Latest Publications
- Open Access
- 28 October 2025
- Published by Springer Nature in Medical Science Educator
- Vol. 36 (1) , 117-121
Gaining Empathy for the Learner: A Way to Identify Unique Themes and Patterns in Medical Student Experiences
A variety of program evaluation tools are used in medical education, including grade-based, narrative, and quantitative methods. While providing valuable feedback, they may not fully capture the lived experiences of the learner. To enhance understanding and empathy for the medical school experience, we conducted ethnographic interviews of learners across all years of training. Emergent themes were compared with feedback from traditional instruments. Our empathetic methods not only confirmed themes identified through conventional evaluations but also revealed additional factors that heavily impacted learners. This highlights the need for empathic, human-centered approaches to generate a holistic picture that better informs programmatic change.
- 28 October 2025
- Published by Springer Nature in Medical Science Educator
- Vol. 36 (1) , 117-121
Open AccessGaining Empathy for the Learner: A Way to Identify Unique Themes and Patterns in Medical Student Experiences
A variety of program evaluation tools are used in medical education, including grade-based, narrative, and quantitative methods. While providing valuable feedback, they may not fully capture the lived experiences of the learner. To enhance understanding and empathy for the medical school experience, we conducted ethnographic interviews of learners across all years of training. Emergent themes were compared with feedback from traditional instruments. Our empathetic methods not only confirmed themes identified through conventional evaluations but also revealed additional factors that heavily impacted learners. This highlights the need for empathic, human-centered approaches to generate a holistic picture that better informs programmatic change.
- Open Access
- 28 August 2020
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 217 (12)
A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy
Adoptive T cell therapy (ACT) with genetically modified T cells has shown impressive results against some hematologic cancers, but efficacy in solid tumors can be limited by restrictive tumor microenvironments (TMEs). For example, Fas ligand is commonly overexpressed in TMEs and induces apoptosis in tumor-infiltrating, Fas receptor–positive lymphocytes. We engineered immunomodulatory fusion proteins (IFPs) to enhance ACT efficacy, combining an inhibitory receptor ectodomain with a costimulatory endodomain to convert negative into positive signals. We developed a Fas-4-1BB IFP that replaces the Fas intracellular tail with costimulatory 4-1BB. Fas-4-1BB IFP-engineered murine T cells exhibited increased pro-survival signaling, proliferation, antitumor function, and altered metabolism in vitro. In vivo, Fas-4-1BB ACT eradicated leukemia and significantly improved survival in the aggressive KPC pancreatic cancer model. Fas-4-1BB IFP expression also enhanced primary human T cell function in vitro. Thus, Fas-4-1BB IFP expression is a novel strategy to improve multiple T cell functions and enhance ACT against solid tumors and hematologic malignancies.
- 28 August 2020
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 217 (12)
Open AccessA Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy
Adoptive T cell therapy (ACT) with genetically modified T cells has shown impressive results against some hematologic cancers, but efficacy in solid tumors can be limited by restrictive tumor microenvironments (TMEs). For example, Fas ligand is commonly overexpressed in TMEs and induces apoptosis in tumor-infiltrating, Fas receptor–positive lymphocytes. We engineered immunomodulatory fusion proteins (IFPs) to enhance ACT efficacy, combining an inhibitory receptor ectodomain with a costimulatory endodomain to convert negative into positive signals. We developed a Fas-4-1BB IFP that replaces the Fas intracellular tail with costimulatory 4-1BB. Fas-4-1BB IFP-engineered murine T cells exhibited increased pro-survival signaling, proliferation, antitumor function, and altered metabolism in vitro. In vivo, Fas-4-1BB ACT eradicated leukemia and significantly improved survival in the aggressive KPC pancreatic cancer model. Fas-4-1BB IFP expression also enhanced primary human T cell function in vitro. Thus, Fas-4-1BB IFP expression is a novel strategy to improve multiple T cell functions and enhance ACT against solid tumors and hematologic malignancies.